Bobby Koeleman

Bobby Koeleman is an Associate Professor at Utrecht University's Department of Clinical Genetics, affiliated with University Medical Center Utrecht (UMC U). His work focuses on genetic causes of neurodevelopmental disorders (NDD) and epilepsy, leveraging large-scale patient cohorts and national networks for genetic sample collection. He collaborates closely with clinical genetics departments to support over 600 patients annually. His strategic programs include Brain Cancer and Brain Developmental Disorders, reflecting cross-disciplinary research priorities.

Research interests emphasize biomarker identification for Dravet syndrome, epilepsy GWAS studies, and precision medicine approaches for seizure management. Notable contributions include pioneering large-scale epilepsy GWAS and somatic mutation analysis in brain tumors. He leads the 'Personalized prediction, treatment and genetics in epilepsy' research group, aiming to improve seizure control and quality of life through tailored therapies.

Key achievements include EU-Fp7 funding for epilepsy pharmacogenomics (2012), NWO-VIDI grants (2010), and Diabetes Fonds Nederland grants (2015). His work integrates genetic diagnostics, clinical trials, and translational research to bridge basic science and patient care.

Grant activities include leadership in multi-national epilepsy genomics consortia. Current projects focus on predicting treatment responses in juvenile myoclonic epilepsy and modeling SCN1A gene function using zebrafish models. Research teams collaborate across neurology, genetics, and bioinformatics disciplines to advance personalized medicine strategies.

Active in the 'Personalized prediction, treatment and genetics in epilepsy' group, he coordinates efforts in biomarker discovery and clinical trial design. Future work aims to expand genetic testing pipelines and implement AI-driven diagnostic tools in clinical practice.